RESULTADOS INVESTIGACIÓN

Resultados: 118

05. CYP3A5

BRASIL

Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C. 2007. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics.  Oct;8(10):1299-306.

05. CYP3A5

ECUADOR

Sinués B, Vicente J, Fanlo A, Mayayo-Sinués E, González-Andrade F, Sánchez-Q D, Martínez-Jarreta B. CYP3A5 3, CYP3A4 1B and MDR1 C3435T genotype distributions in Ecuadorians. Dis Markers. 2008;24(6):325-31.

05. CYP3A5

EL SALVADOR

Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007 Aug;29(4):412-6.

05. CYP3A5

ESPAÑA

Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007 Aug;29(4):412-6.

Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between  Spaniards and Other Caucasian populations. Ther Drug Monit. 2005 Dec;27(6):819-21.

Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, García M, Diaz-Rubio M, Agúndez JA. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007 Jul 2;7:118.

05. CYP3A5

NICARAGUA

Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz  I, Martinez-Jarreta B. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007 Aug;29(4):412-6.

05. CYP3A5

PORTUGAL

Oliveira E, Marsh S, van Booven DJ, Amorim A, Prata MJ, McLeod HL. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics. 2007 Jul;8(7):703-12. doi: 10.2217/14622416.8.7.703.

05. CYP3A5

AMÉRICA CENTRAL

Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, Conde B, Arenaz I, Martinez-Jarreta B. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007 Aug;29(4):412-6.

06. CYP2A6

BRASIL

Rossini A, Lima SS, Rapozo DC, Faria M, Albano RM, Pinto LF. CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro. Braz J Med Biol Res. 2006 Feb;39(2):195-201.

Rossini A, Rapozo DC, Soares Lima SC, Guimarães DP, Ferreira MA, Teixeira R, Kruel CD, Barros SG, Andreollo NA, Acatauassú R, Matos HJ, Albano RM, Pinto LF. Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population. Carcinogenesis. 2007 Dec;28(12):2537-42.

Vasconcelos GM, Struchiner CJ, Suarez-Kurtz G. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenomics J. 2005;5(1):42-8.

06. CYP2A6

CHILE

Cáceres DD, Alvarado SA, Martínez P, Quiñones LA. [Relation of genetic variants of CYP2A6 with tobacco dependence and smoking habit in Chilean subjects. A pilot study]. Rev Med Chil. 2012 Apr;140(4):436-41.

06. CYP2A6

ECUADOR

Soriano A, Vicente J, Carcas C, Gonzalez-Andrade F, Arenaz I, Martinez-Jarreta B, Fanlo A, Mayayo E, Sinués B. Differences between Spaniards and Ecuadorians in  CYP2A6 allele frequencies: comparison with other populations. Fundam Clin Pharmacol. 2011 Oct;25(5):627-32.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies